Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial
Clinical and Translational Science · 2026-04 · 19 (4)
DOI: 10.1111/cts.70560 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 21.04.2026. Verfasst von Ramesh R Boinpally und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Pyridines, Pyrroles, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Ubrogepant (Ubrelvy), a CGRP receptor antagonist, is approved for acute treatment of migraine with or without aura in adults. Because ubrogepant treats a neurological condition, it is of interest to know central nervous system exposure. Ubrogepant concentrations in plasma and cerebrospinal fluid (CSF) were measured in participants with a history of migraine. This analysis included a subset of participants with a ≥ 1 year history of migraine who were enrolled in a Phase 1b multi‐center, open‐label trial and who underwent a single CSF collection via lumbar puncture. All participants received a single oral dose of 100 mg ubrogepant. Plasma and CSF ubrogepant concentrations were measured using LC–MS/MS at pre‐defined post‐dose timepoints (plasma: 0–24 h; CSF: 2 or 4 h). Ubrogepant CSF/plasma concentration ratios at 2 and 4 h were determined. Ubrogepant safety and tolerability were evaluated through reporting of treatment‐emergent adverse events (TEAEs; ≤ 30‐days after dosing), physical examination, ECG, laboratory testing, and vital sign monitoring. A total of 8 participants were included. Mean (±SD) age was 34.5 ± 9.58 years and 4 participants (50%) were male. At 2 h, mean (±SD) CSF and plasma ubrogepant concentrations were 1.1 ± 0.8 and 354 ± 163 ng/mL, respectively (CSF/plasma ratio: 0.36% ± 0.29%); at 4 h, 2.3 ± 1.9 and 218 ± 84 ng/mL, respectively (CSF/plasma ratio: 0.94% ± 0.64%). No serious TEAEs, deaths, or significant changes in laboratory values, vital signs, or ECGs occurred. Because ubrogepant half maximal effective concentration (EC 50 ) has been estimated at ~1.4 ng/mL, ubrogepant could act both centrally and peripherally to relieve migraine symptoms. ClinicalTrials.gov , NCT04179474 (registration date: 27 November 2019).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
- Clinical Development, AbbVie Inc., North Chicago, Illinois, USA.
ORCID-Profile: Ramesh R Boinpally, Joel M Trugman
Zitieren
APA
Boinpally, R. R., & Trugman, J. M. (2026). Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial. Clinical and Translational Science, 19(4). https://doi.org/10.1111/cts.70560
Vancouver
Boinpally RR, Trugman JM. Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial. Clinical and Translational Science. 2026;19(4). doi:10.1111/cts.70560
BibTeX
@article{Boinpally2026,
author = {Boinpally, Ramesh R and Trugman, Joel M},
title = {Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open‐Label Trial},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {4},
doi = {10.1111/cts.70560}
}
EUVIMED